- Home
- BLIN vs BCTX Comparison
BLIN vs BCTX Comparison
Compare BLIN & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- BCTX
- Stock Information
- Founded
- BLIN 2000
- BCTX 2014
- Country
- BLIN United States
- BCTX Canada
- Employees
- BLIN N/A
- BCTX N/A
- Industry
- BLIN EDP Services
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- BCTX Health Care
- Exchange
- BLIN Nasdaq
- BCTX Nasdaq
- Market Cap
- BLIN 16.0M
- BCTX 16.1M
- IPO Year
- BLIN 2007
- BCTX N/A
- Fundamental
- Price
- BLIN $1.67
- BCTX $5.20
- Analyst Decision
- BLIN Strong Buy
- BCTX Strong Buy
- Analyst Count
- BLIN 1
- BCTX 1
- Target Price
- BLIN $4.62
- BCTX $32.00
- AVG Volume (30 Days)
- BLIN 76.6K
- BCTX 3.4M
- Earning Date
- BLIN 05-13-2025
- BCTX 06-13-2025
- Dividend Yield
- BLIN N/A
- BCTX N/A
- EPS Growth
- BLIN N/A
- BCTX N/A
- EPS
- BLIN N/A
- BCTX N/A
- Revenue
- BLIN $15,394,000.00
- BCTX N/A
- Revenue This Year
- BLIN $4.89
- BCTX N/A
- Revenue Next Year
- BLIN $10.49
- BCTX N/A
- P/E Ratio
- BLIN N/A
- BCTX N/A
- Revenue Growth
- BLIN N/A
- BCTX N/A
- 52 Week Low
- BLIN $0.76
- BCTX $0.35
- 52 Week High
- BLIN $2.80
- BCTX $9.82
- Technical
- Relative Strength Index (RSI)
- BLIN 57.76
- BCTX 59.15
- Support Level
- BLIN $1.46
- BCTX $3.75
- Resistance Level
- BLIN $1.60
- BCTX $9.82
- Average True Range (ATR)
- BLIN 0.11
- BCTX 0.89
- MACD
- BLIN 0.00
- BCTX 0.16
- Stochastic Oscillator
- BLIN 96.67
- BCTX 24.88
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.